All Posts By

Graviton

Graviton
0
PRESS RELEASES
10/2017

3-V Biosciences to Present Clinical Data Demonstrating TVB-2640 Inhibits Fatty Acid Synthesis at The Liver Meeting 2017®

Menlo Park, California, October 16, 2017. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics for metabolic diseases and oncology, announced today that it will present data on its first-in-class…
Read More
Graviton
6
Oncology
04/2017

First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640

AACR Annual Meeting
Read More
Graviton
6
NASH
04/2017

Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for the treatment of NASH

EASL International Liver Congress
Read More
Graviton
6
Oncology
12/2016

Heavily Pre-Treated Breast Cancer Patients show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 in Combination with Paclitaxel

San Antonio Breast Cancer Symposium
Read More
Graviton
6
NASH
11/2016

Pharmacological inhibition of FASN Prevents High Fat Diet Induced Liver Damage in Mice and Significantly Reduces de novo Lipogenesis in Humans

AASLD The Liver Meeting
Read More
Graviton
4
Oncology
11/2016

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase Inhibitor, TVB-2640

NCRI Cancer Conference
Read More
Graviton
0
PRESS RELEASES
11/2016

3-V Biosciences to Present Data at the American Association for the Study of Liver Diseases Annual Meeting 2016 in Boston, MA

Menlo Park, California, November 04, 2016. 3-V Biosciences, Inc., a clinical-stage pharmaceutical company developing therapeutics for liver diseases, including non-alcoholic steatohepatitis (NASH), and oncology announced today that it has been…
Read More
Graviton
4
Oncology
06/2016

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640

ASCO Annual Meeting
Read More
Graviton
4
Oncology
04/2016

FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study

AACR Annual Meeting
Read More
Graviton
4
Oncology
04/2016

Preclinical studies characterize tumor type sensitivity to FASN inhibition and the mechanism and efficacy of novel drug combinations with TVB-2640

AACR Annual Meeting
Read More